NYXOAH SA NPV

ISIN: BE0974358906 WKN: - Asset Class: Stock

Company 2024/08/15 17:26:48 **Price 7.20** EUR

Difference 2-2.44%(-0.18)

Contact Details

NYXOAH SA Tel: +32-10-22-23-55

-- Fax: +

Rue Edouard Belin 12 Web: http://www.nyxoah.com
1435 Mont-Saint-Guibert E-mail: info@nyxoah.com



Company Profile

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	23	20:	22	202	21
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	68,351,000		100,260,000		140,060,000	
Common stock capital		4,926,000		4,440,000		4,427,000
Fixed assets	55,806,000		45,811,000		32,087,000	
Equity capital of a company		98,112,000		120,334,000		149,276,000
Cash and cash equivalents	21,610,000		17,888,000		135,509,000	
Accrued liabilities		194,000		59,000		92,000
Other assets	-		-		-	
Current liabilities		14,353,000		14,903,000		10,918,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		11,692,000		10,834,000		11,953,000
Different income		-		-		-
Other liabilities		0		0		0
Total assets	124,157,000	124,157,000	146,071,000	146,071,000	172,147,000	172,147,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	147	138	106
Equity ratio	79.02%	82.38%	86.71%
Debt-equity ratio	26.55%	21.39%	15.32%

Others

	2023	2022	2021
Tax Expense Rate	3.24%	-3.89%	-12.09%

NYXOAH SA NPV

ISIN: BE0974358906 WKN: - Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	4,348,000	3,084,000	852,000
Net income	-43,212,000	-31,225,000	-27,619,000
EBIT	-46,021,000	-29,266,000	-23,016,000
Operating income before taxes	-44,657,000	-30,056,000	-24,639,000
Cash Flow	-45,021,000	-28,923,000	-25,729,000
Net interest income	1,364,000	-790,000	-1,623,000
Research and development expenses	25,333,000	14,843,000	4,232,000
Income taxes	-1,445,000	1,169,000	2,980,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	29,578	22,348	8,038

Board of Directors		
Debest Tour	Obsigned of Oversalization Passel	
Robert Taub	Chairman of Supervisory Board	
Jürgen Hambrecht	Member of Supervisory Board	
Pierre Gianello	Member of Supervisory Board	
Daniel Wildman	Member of Supervisory Board	
Kevin Rakin	Member of Supervisory Board	
Rita Johnson-Mills	Member of Supervisory Board	
Virginia Kirby	Member of Supervisory Board	

Members of Management Board		
Olivier Taelman	Chairman of Managing Board	
An Moonen	Member of Executive Committee	
Bruno Onkelinx	Member of Executive Committee	
Chris Eigenmann	Member of Executive Committee	
David DeMartino	Member of Executive Committee	
Loic Moreau	Member of Executive Committee	